← Back to Clinical Trials
RecruitingNCT05756244

PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionPregnancy Related
SponsorUniversity of Calgary
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment825
SexFEMALE
Min Age18 Years
Max Age60 Years
Start Date2023-04-04
Completion2029-06-30

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The PREP and GO study is an international multicentre prospective cohort evaluating anticoagulation management strategies around labor and delivery and the postpartum period.

Eligibility Criteria

Inclusion Criteria: * 18 years of age or older * Requires anticoagulation during the antepartum period of pregnancy for a VTE indication, including at least one of: 1. Objectively confirmed VTE (DVT, superficial vein thrombosis \[SVT\], PE or unusual site thrombosis) diagnosed during the current pregnancy; 2. Objectively confirmed VTE diagnosed in a prior pregnancy; 3. Objectively confirmed VTE diagnosed when not pregnant; 4. Inherited or acquired thrombophilia requiring anticoagulation. * Receiving any dose or type of LMWH during the antepartum period Exclusion Criteria: * Anticoagulation for a non-VTE indication, including prosthetic heart valves, atrial fibrillation, prevention of placenta-mediated pregnancy complications, or prevention of recurrent pregnancy loss (participants can be included with a diagnosis of antiphospholipid syndrome (APS) with or without thrombotic events) * Unable to provide or declined consent. * Home or birthing centre planned delivery.

Related Trials